timothy sykes logo
Tempus AI (TEM) Rallies As Upgrade, Earnings And Personalis Deal Align Thumbnail
G Google News

Tempus AI (TEM) Rallies As Upgrade, Earnings And Personalis Deal Align

ELLIS HOBBS•UPDATED SEP. 15, 2026, 12:33 PM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

Tempus AI Inc. stocks have been trading up by 6.61 percent after strong AI healthcare partnership news boosted investor optimism.

Key Takeaways

  • Piper Sandler upgraded Tempus AI to Overweight and lifted its price target to $76, leaning on the Personalis acquisition thesis and positive INTerpath-001 MRD data.
  • The company is framed as a scaled precision-medicine and data-licensing player built around multimodal “context is the asset” datasets.
  • Q2 2026 for Tempus AI delivered 22% revenue growth to $382.5M and a clean swing to positive net income and EBITDA.
  • Tempus AI plans to buy Personalis for $16.25 per share in a roughly $1.5B enterprise-value deal to deepen tumor-informed MRD and sequencing.
  • A seller-side shareholder review is examining whether Personalis is being sold fairly, described as a routine deal-fairness check.

Candlestick Chart

Live Update At 12:32:42 EDT: On Tuesday, September 15, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 6.61%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Tempus AI, trading under ticker TEM, has been acting like a momentum name with real numbers behind it. On the daily chart, TEM climbed from a $57.73 close on 2026/09/14 to $66.33 on 2026/09/15. That’s a sharp, multi-day squeeze off recent lows near the high‑50s and low‑60s, showing strong dip demand.

Intraday, TEM’s 5‑minute tape on 2026/09/15 shows a clean trend day. The stock opened near $62, pushed steadily, and held higher lows all session, grinding into the mid‑$66 area by midday. For short‑term traders, that kind of staircase price action often signals aggressive buyers absorbing every pullback.

Fundamentals are finally lining up with the chart. Tempus AI posted Q2 2026 revenue of $382.5M, up 22% year over year, and flipped from losses to positive net income and EBITDA. A 73.5% gross margin tells you TEM’s precision‑medicine and data business throws off rich unit economics even as overall profit margins are still negative on a trailing basis.

More Breaking News

Leverage is meaningful, with enterprise value around $11.9B and long‑term debt north of $1.3B, but liquidity looks solid. Tempus AI reports a current ratio of 3.3 and more than $599M in cash, giving the company runway to keep funding growth and the Personalis deal without staring down an immediate cash crunch.

Why Traders Are Watching TEM Right Now

TEM is sitting in the sweet spot where story, numbers, and catalysts are finally lining up. The core story is that Tempus AI is not just another AI buzzword play; it is a scaled precision‑medicine diagnostics and data‑licensing company. Its edge is a massive pool of multimodal clinical and molecular data, the kind of “context is the asset” dataset that AI models need to actually matter in drug discovery and oncology care.

Q2 2026 results gave that story teeth. Tempus AI pushed revenue to $382.5M, up 22% year over year, while improving gross profit and swinging to positive net income and EBITDA. For traders, this is critical: TEM has moved from a pure “promise” name toward a business with scale and operating leverage. When high‑growth names cross that line, institutions often get more comfortable building positions.

Wall Street is already responding. Piper Sandler upgraded Tempus AI to Overweight from Neutral and raised its price target to $76 from $56. The firm specifically called out the pending acquisition of Personalis and the combined tumor‑informed MRD and sequencing platform after positive INTerpath‑001 data. That kind of $20 target hike tells traders that at least one major desk sees upside in the medium term.

The Personalis deal itself — $16.25 per share, valuing the target around $1.5B in enterprise value — is the other big piece of the puzzle. Tempus AI is effectively doubling down on minimal residual disease testing and tumor sequencing, linking its data engine with Personalis’s MRD capabilities. A routine shareholder investigation on the Personalis side is reviewing deal fairness, but it’s framed as standard governance, not a direct challenge to TEM. Traders should still watch for any delay headlines but, for now, the market is focused on the synergy story, not the legal noise.

Conclusion

Tempus AI is stepping into a new phase, and traders are treating TEM like it. The stock is breaking higher on strong volume, backed by a 22% revenue jump, margin improvement, and the first print of positive net income and EBITDA in Q2 2026. That combination alone puts Tempus AI on many momentum screens.

Layer on the Personalis acquisition, and you get a clear strategic push. Tempus AI wants to own the full stack of tumor‑informed MRD and sequencing while feeding its multimodal datasets into AI‑driven drug discovery. Piper Sandler’s upgrade to Overweight, with a price‑target bump to $76, is Wall Street’s way of saying the strategy looks credible at scale.

None of this removes risk. Tempus AI still carries heavy losses on a trailing basis, high price‑to‑sales and price‑to‑book multiples, and a leveraged balance sheet. Integration of Personalis will be complex, and the fairness review on the seller side is a background overhang, even if it is described as routine.

For active traders, the key is discipline. As Tim Sykes likes to remind his community, “The market rewards those who prepare, not those who hope.” As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. With TEM, that means tracking the trend, watching how the stock reacts to each new update on Q3 numbers and the Personalis close, and being ready to cut quickly if the story or price action breaks — or to ride the momentum if execution keeps matching the hype.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”